Klinische Studien

Clinical trial titleZentrum
Cell-specific transcorneal electrostimulation (TES) as rehabilitation and support tool for gene therapy in retinis pigmentosaTübingen
Rate of Progression in USH2A Related Retinal DegenerationTübingen
Rate of Progression in EYS Related Retinal DegenerationTübingen
Rate of Progression of PCDH15-Related Retinal Degeneration in UsherTübingen
Natural history of the progression of X-linked retinitis pigmentosa.Tübingen
Bringing Gene Supplementation Therapy for Inherited PDE6A- and CNGA3-associated Retinopathies into Clinical Practice: A joint Tübingen-München Project Acronym (www.rd-cure.de)Tübingen
Belite Bio = DRAGON = Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent SubjectsTübingen
A Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study to Evaluate the Safety and Tolerability of ATSN-201 Gene Therapy in Male Subjects with RS1-Associated X-linked RetinoschisisTübingen
Analyse der klinischen Untersuchungen von Patienten mit Netzhautdystrophien nach Behandlung mit Voretigene neparvovec (LuxturnaTM)Tübingen
Klinische Charakterisierung BEST ErkrankungTübingen
CNGB1 Retinitis Pigmentosa and Allied DisordersTübingen
Klinische Charakterisierung CNGA1 Retinitis pigmentosaTübingen
Clinical and Socio-demographic Characteristics of Patients with X-linked- Retinitis Pigmentosa (XLRP) and Impact of the DiseaseTübingen
Study to Determine Presence of Genetically Confirmed CNGA3- and CNGB3-Associated Achromatopsia Patients at Investigational Sites for Potential Participation in Future Clinical Research StudiesTübingen
Retrospective Non-Interventional Study to Evaluate the Patient Benefit of Transcorneal Electrostimulation (TES)Tübingen
Observational Study for Patients Treated with voretigene NepravovecTübingen
A double-masked, randomized, controlled, multiple-dose study to evaluate the efficacy, safety, tolerability and systemic exposure of QR-110 in Subjects with Leber’s Congenital Amaurosis (LCA) due to c.2991+1655A>G mutation (p.Cys998X) in the CEP290 gene (Illuminate).Tübingen
Safety and efficacy of a bilateral single subretinal injection of rAAV.hCNGA3 in adult and minor patients with CNGA3-linked achromatopsia investigated in a randomized, wait list controlled, observer-masked trialTübingen
Multi-national, multi-centre, double-masked, placebo-controlled proof of concept trial to evaluate the safety and efficacy of oral soraprazan in Stargardt diseaseTübingen
A Phase 2, randomized, concurrent-controlled study of AAV8-hCARp.hCNGB3 gene therapy for the treatment of achromatopsia associated with variants in the CNGB3 geneTübingen
An open-label, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of Sepofarsen in Pediatric Subjects of Age 3 to <8 Years with Leber Congenital Amaurosis (LCA) due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 GeneTübingen
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene with Early to Moderate Vision LossTübingen
A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety and Tolerability of QR-421a in Subjects with Retinitis Pigmentosa (RP) due to Mutations in Exon 13 of the USH2A Gene with Advanced Vision LossTübingen
Evaluation der Wirksamkeit einer transkornealen Elektrostimulation bei Patienten mit Retinitis Pigmentosa – eine multizentrische, prospektive, randomisierte, kontrollierte und doppel-blinde Studie im Auftrag des Gemeinsamen Bundesausschusses (G-BA)Tübingen
PDE6A gene therapy for retinitis pigmentosaTübingen
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)Gießen
An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. (BRIGHTEN)Gießen
Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR GeneGießen
Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR GeneGießen
A multicenter, multinational, randomized, double-blind, placebo-controlled study to assess the efficacy, pharmacodynamics, pharmacokinetics, safety, and tolerability of venglustat in late-onset GM2…Gießen
A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic FibrosisGießen
Percieve – Nicht-interventionelle Studie (NIS) zur Beobachtung von Patienten mit RPE65-assoziierter Netzhautdegeneration, die mit dem Medikament LTW888 behandelt wurden. Ziel ist es, die Unbedenklichkeit und den Langzeitverlauf der Behandlung zu untersuchen.Gießen